Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)
Description: 

This will be a prospective study to measure the impact of MammaPrint and BluePrint on treatment decisions in breast cancer patients. The primary objective will be to measure the impact of MammaPrint and BluePrint on treatment decisions in stage I and II HR-positive, HER2-negative breast cancer patients. As a secondary objective, the impact of MammaPrint and BluePrint on treatment will be assessed in patients with T1a/T1b and pN0/pN1 (up 1 node) Triple Negative or HER2-positive breast cancer.

Study Number: 

PH 280515

Phase: 
N/A
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT02670577

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.